Literature DB >> 27738381

Valproic Acid and Hepatic Steatosis: A Possible Link? About a Case Report.

Leila Mnif1, Rim Sellami1, Jawaher Masmoudi1.   

Abstract

BACKGROUND: Valproic acid is a mood-stabilizing anticonvulsant. Hepatic injuries are among the occasionally observed adverse effects of this medication. CASE
PRESENTATION: We present the case of a 47-year-old man who had bipolar disorder for ten years and treated with valproic acid. He demonstrated elevated serum aminotransferases and ultrasonography revealed that hepatomegaly was suggestive of hepatic steatosis.
CONCLUSION: This case report stresses the importance of a complete drug history and the need for clinicians to be aware of the delayed onset of hepatic injuries.

Entities:  

Keywords:  anticonvulsivant; bipolar disorder; hepatic steatosis; valproic acid

Mesh:

Substances:

Year:  2016        PMID: 27738381      PMCID: PMC5044469     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  17 in total

1.  [Treatment with valproate and hepatic steatosis].

Authors:  R Ortiz-Sáenz de Santa María; C Santiago-Fernández; M Cano-Del Pozo; O Pérez-Gil; M I Soto-Alvarez; E Barriuso-Pérez; J A Moche-Loeri
Journal:  Rev Neurol       Date:  2005 Dec 16-31       Impact factor: 0.870

2.  Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats.

Authors:  Li-fang Zhang; Ling-sheng Liu; Xiao-man Chu; Hao Xie; Li-juan Cao; Cen Guo; Ji-ye A; Bei Cao; Meng-jie Li; Guang-ji Wang; Hai-ping Hao
Journal:  Acta Pharmacol Sin       Date:  2014-01-20       Impact factor: 6.150

Review 3.  Hepatotoxicity to sodium valproate: a review.

Authors:  P R Powell-Jackson; J M Tredger; R Williams
Journal:  Gut       Date:  1984-06       Impact factor: 23.059

4.  Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites.

Authors:  M F Silva; J P Ruiter; L IJlst; P Allers; H J ten Brink; C Jakobs; M Duran; I Tavares de Almeida; R J Wanders
Journal:  Anal Biochem       Date:  2001-03-01       Impact factor: 3.365

Review 5.  Valproate: past, present, and future.

Authors:  Cecilie U Johannessen; Svein I Johannessen
Journal:  CNS Drug Rev       Date:  2003

6.  Fatal liver failure in 16 children with valproate therapy.

Authors:  D Scheffner; S König; I Rauterberg-Ruland; W Kochen; W J Hofmann; S Unkelbach
Journal:  Epilepsia       Date:  1988 Sep-Oct       Impact factor: 5.864

7.  Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis.

Authors:  Cátia C P Aires; Lodewijk Ijlst; Femke Stet; Carina Prip-Buus; Isabel Tavares de Almeida; Marinus Duran; Ronald J A Wanders; Margarida F B Silva
Journal:  Biochem Pharmacol       Date:  2009-10-23       Impact factor: 5.858

8.  Valproate-induced hepatic injury: analyses of 23 fatal cases.

Authors:  H J Zimmerman; K G Ishak
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

Review 9.  Advances in the understanding and treatment of nonalcoholic fatty liver disease.

Authors:  Stephen A Harrison; Adrian M Di Bisceglie
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.

Authors:  M F B Silva; C C P Aires; P B M Luis; J P N Ruiter; L IJlst; M Duran; R J A Wanders; I Tavares de Almeida
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

View more
  1 in total

Review 1.  New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants.

Authors:  Mauro Cataldi; Vincenzo Citro; Chiara Resnati; Federica Manco; Giovanni Tarantino
Journal:  Adv Ther       Date:  2021-03-24       Impact factor: 3.845

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.